MedTrace Logo

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

NCT00200525 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2005-12-16

No results posted yet for this study

Summary

Study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.

Conditions

  • Parkinson Disease

Interventions

DRUG

apomorphine HCl injection

Sponsors & Collaborators

  • Mylan Bertek Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Will Sullivan · Mylan Bertek Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Completion
2002-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00200525 on ClinicalTrials.gov